Sector Expert: Eden Rahim

Next Edge Capital , Theta Strategies Capital

Image: Eden Rahim

Eden Rahim is portfolio manager and option strategist at Next Edge Capital. He manages the Next Edge Biotech Plus Fund and the Next Edge Theta Yield Fund. His experience includes two decades of portfolio and hedge fund money management, as well as work as an options strategist, derivatives and biotech analyst and portfolio manager. Rahim has managed and traded an options book spanning 250+ securities globally and four commodities, with open interest of 500,000 contracts in addition to 14 covered call ETFs (over $0.5B AUM) in Canada, the U.S. and Australia, employing his options writing discipline at Horizons Exchange-Traded Funds. Rahim possessed a top-quartile, five-year, five-star growth fund portfolio manager track record on over $1B in assets across four mandates at RBC Global Asset Management. In addition, Rahim has delivered a +26% compounded annual return across a biotechnology mandate between 1995-2003. He also has extensive institutional hedging experience through major crises, and experience in the structuring of notes to create specific payoff profiles.



Recent Interviews

Embrace Low-Cap Biotech for High Gains: Eden Rahim of Next Edge Capital (3/2/16)
vialdrop630

Eden Rahim of Toronto-based Next Edge Capital has had his share of multibagger and grand-slam successes, and is one of the few mutual fund managers who feels comfortable investing in micro-cap biotech names side-by-side with billion-dollar biotech stocks. In this interview with The Life Sciences Report, Rahim describes a group of micro-, small- and mid-cap biotech names possessing powerful growth drivers that could perform even when the overall market is not so hot.

Harness Biotech Volatility with an Options Strategy: Theta Strategy Capital's Eden Rahim (8/12/15)
pillstubesdna580

Volatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That's the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies Capital. Can you grow a portfolio if some of your more successful names are called away by option buyers before the stock goes into the stratosphere? The answer is yes, and in this interview with The Life Sciences Report, Rahim describes his technique and leaves readers with six names that he fully expects to reap very large gains.

Recent Quotes

"RP management has secured a partnership with Shiseido Company in Japan to fund its alopecia trials."

The Life Sciences Report Interview with Eden Rahim (3/2/16)
more >

"When I can get potential blue-sky regenerative technologies like RP's at this small valuation, I'm buying."

The Life Sciences Report Interview with Eden Rahim (8/12/15)
more >

"BCLI is an inexpensive way to get exposure to a potential blockbuster technology."

The Life Sciences Report Interview with Eden Rahim (8/12/15)
more >

"CPHR is a decent risk/reward proposition."

The Life Sciences Report Interview with Eden Rahim (8/12/15)
more >



Due to permission requirements, not all quotes are shown.